TUNICRIS-julkaisut - Trepo

Viitteet 1-1 / 1

Long-term patient-reported outcomes from monarchE : Abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer

Tolaney, Sara M.; Guarneri, Valentina; Seo, Jae Hong; Cruz, Josefina; Abreu, Miguel Henriques; Takahashi, Masato; Barrios, Carlos; McIntyre, Kristi; Wei, Ran; Munoz, Maria; Antonio, Belen San; Liepa, Astra M.; Martin, Miguel; Johnston, Stephen R.D.; Kellokumpu-Lehtinen, Pirkko Liisa; Harbeck, Nadia (03 / 2024)
article

Background: In monarchE, abemaciclib demonstrated a sustained benefit in invasive disease-free survival and a tolerable safety profile at 42-months median follow-up. With no expected disease-related symptoms, therapies in ...